VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Updates at ASH 2020 on bispecific antibodies in MM

Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses the progress being made in the field of bispecific antibodies in multiple myeloma. Data will be presented at ASH 2020 surrounding the use of BCMA-targeted bispecifics, but there will also be reports of highly effective novel antibodies that may become second-generation therapies, including talquetamab and cevostamab. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Joshua Richter, MD, has undertaken consultancy work for Takeda.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter